Opioid-Associated Disease Prevention and Outreach Programs - Appeals and Membership of Standing Advisory Committee
SB 224 makes targeted changes to Maryland’s law governing Opioid-Associated Disease Prevention and Outreach Programs, which are local or community-based syringe services and outreach programs intended to reduce disease transmission and connect participants to treatment. The bill does not create a new program; instead, it updates the administrative process for approving and overseeing these programs.
First, the bill changes who hears an appeal when the Maryland Department of Health and a local health officer deny an application to operate a program. Under the bill, the appeal goes to the Secretary of Health or the Secretary’s designee, rather than specifically to the Deputy Secretary for Public Health Services. The bill also revises the membership and chairmanship language for the Standing Advisory Committee on Opioid-Associated Disease Prevention and Outreach Programs so that the Secretary or the Secretary’s designee serves in those roles.
The bill preserves the core duties of these programs: outreach, education, linkage to substance use treatment and recovery services, and distribution and collection of hypodermic needles and syringes. It also keeps the Department’s responsibility to adopt regulations, provide technical assistance, and establish procedures for security, appeals, data collection, and program evaluation. The effective date is July 1, 2025.
The bill’s impact on state law is limited but important procedurally. It amends provisions in the Health-General Article to streamline or broaden administrative authority within the Department of Health, while leaving the underlying authorization framework for opioid-associated disease prevention and outreach programs intact. It also updates the advisory committee structure to reflect the Secretary’s direct oversight or delegation authority.
The general sentiment reflected in the voting history is strongly supportive and noncontroversial: the bill passed both chambers unanimously, with 46-0 in the Senate and 131-0 in the House. No committee transcript discussion was provided, and the unanimous votes suggest broad agreement on the administrative and technical nature of the changes. The main point of contention, if any, appears to be minimal; the bill does not alter the substance of harm-reduction services, but rather adjusts appeal routing and committee membership language.
SB 224 amends the Health-General Article provisions governing Opioid-Associated Disease Prevention and Outreach Programs by changing the appeal path for denied program applications from the Deputy Secretary for Public Health Services to the Secretary of Health or the Secretary’s designee, and by revising the membership/chair language for the Standing Advisory Committee. It leaves intact the existing authorization, operational, technical assistance, security, data collection, and evaluation requirements for these programs, while giving the Department updated administrative authority over appeals and advisory oversight.
The bill appears to have been viewed as a routine, technical update rather than a policy shift. It passed the Senate 46-0 and the House 131-0, indicating unanimous bipartisan support and no recorded opposition in the voting history provided. With no committee transcript excerpts available, there is no evidence of significant debate, and the overall sentiment is strongly favorable.
No notable contention is evident in the materials provided. The bill’s changes are administrative: it reassigns appeal authority to the Secretary or designee and updates the advisory committee’s composition and chair designation. Because the bill does not expand or restrict the underlying harm-reduction program model, any disagreement would likely have centered on internal departmental structure rather than on opioid outreach, syringe services, or treatment linkage policy, but no such disagreement is reflected in the record provided.